Klebsiella pneumoniae Carbapenemase (KPC)

Klebsiella pneumoniae Carbapenemase (KPC) is a mobile Ambler Class A (Bush–Jacoby Group 2f) active-site serine β-lactamase encoded by the blaKPC gene (~882 bp, encoding a 293-amino-acid pre-protein of ~28.5 kDa after signal peptide cleavage). First isolated in 1996 from a carbapenem-resistant Klebsiella pneumoniae strain in North Carolina and reported by H. Yigit and colleagues in 2001, KPC enzymes (predominantly the pandemic alleles blaKPC-2 and blaKPC-3) confer broad-spectrum antimicrobial resistance against penicillins, first- through fourth-generation cephalosporins, the monobactam aztreonam, and all carbapenems (imipenem, meropenem, ertapenem, and doripenem).

Whereas Class B enzymes such as New Delhi Metallo-Beta-Lactamase 1 (NDM-1) use catalytic zinc ions, KPC operates via a two-step covalent acylation–deacylation cycle driven by the nucleophilic hydroxyl group of Ser70 (Ambler standard numbering). Over the past two decades, blaKPC-2 and blaKPC-3 have become the dominant carbapenemases in healthcare-associated Enterobacterales across North and South America, Europe, and East Asia—propelled both by the clonal expansion of high-risk K. pneumoniae clonal group 258 (CG258, comprising ST258 and ST11) and by rapid horizontal gene transfer of the Tn4401 transposon across conjugative IncFII, IncN, and IncX3 plasmid replicons.

The Ser70 Acylation–Deacylation Cycle and Oxyanion Hole

In common with non-carbapenemase Class A β-lactamases (TEM-1, SHV-1, and CTX-M-15), KPC folds into a globular α/β domain containing a five-stranded antiparallel β-sheet sandwiched between two helical clusters, with the catalytic cleft located at the domain interface. The active site houses three conserved Class A sequence motifs:

1. S70-X-X-K73: Contains the catalytic nucleophile Ser70 and the general base Lys73.
2. S130-D131-N132 (SDN loop): Positions the substrate and participates in proton shuttle networks between Ser70 and the leaving β-lactam ring nitrogen.
3. K234-T235-G236 (KTG triad) and the Ω-loop (Arg164–Asp179): Anchors the C3/C4 carboxylate of the antibiotic and positions the essential deacylating general base Glu166.

During acylation, Lys73 and Glu166 (acting through a bridging catalytic water molecule) abstract a proton from the Ser70 γ-hydroxyl group, which attacks the electrophilic β-lactam carbonyl carbon to form a tetrahedral oxyanion intermediate stabilized by the backbone amide NH groups of Ser70 and Thr237 (the oxyanion hole). Collapse of this tetrahedral state cleaves the β-lactam C–N bond and yields a covalent acyl-enzyme ester intermediate. During deacylation, Glu166 on the Ω-loop activates a conserved hydrolytic water molecule (held in place by Asn170) to attack the acyl-enzyme carbonyl carbon, releasing the hydrolyzed, biologically inactive β-lactam ring and regenerating free Ser70.

Why KPC Hydrolyzes Carbapenems While TEM-1 and CTX-M Cannot

In classical Class A β-lactamases (TEM-1 or CTX-M-15), carbapenems act as "suicide substrates": after acylation of Ser70, the characteristic C6 α-1*R*-hydroxyethyl side chain of imipenem or meropenem forms a hydrogen bond with Asn132/Glu166 and sterically displaces or disorients the hydrolytic water molecule, trapping the enzyme in an inactive acyl-enzyme state (and allowing pyrroline Δ² → Δ¹ tautomerization).

X-ray crystallography by Clyde Smith, Robert Bonomo, Wladek Minor, and colleagues demonstrated how KPC-2 overcomes this deacylation block:

• A Disulfide-Constrained, Shallower Active Site (Cys69–Cys238): A conserved disulfide bridge between Cys69 and Cys238 repositions the Ser70 backbone outward by ~0.8–1.0 Å and widens the entrance of the catalytic pocket.
• Hydrophobic and Cation–π Gatekeeping by Trp105 and Thr237: At the mouth of the cleft, the indole ring of Trp105 (replacing Tyr105 in TEM-1) together with Leu167 on the Ω-loop provides conformational flexibility that accommodates the C6 α-hydroxyethyl substituent without colliding with the deacylating water molecule. As a result, Glu166 and Asn170 remain productively aligned to hydrolyze the carbapenem acyl-enzyme intermediate with a turnover number (k_cat) of 3 to 25 s⁻¹.

The Tn4401 Transposon and IncFII Plasmid Dissemination

Across clinical Enterobacterales, blaKPC-2 and blaKPC-3 are almost universally mobilized within Tn4401, a 10.0-kb active Tn3-family replicative transposon bounded by 39-bp imperfect inverted repeats. Tn4401 encodes a transposase (tnpA), a resolvase (tnpR), and two unrelated insertion sequences—ISKpn7 (upstream of blaKPC) and ISKpn6 (downstream of blaKPC)—generating a 5-bp target-site duplication upon transposition. Variations in the 100-to-255-bp non-coding region between ISKpn7 and the blaKPC start codon define at least nine polymorphic isoforms (Tn4401a through Tn4401i): Tn4401b represents the full-length prototype, Tn4401a contains a 99-bp deletion that brings a stronger tandem P1 + P2 promoter configuration closer to blaKPC (increasing enzyme expression), and Tn4401d carries a 68-bp deletion.

In China and East Asia, where K. pneumoniae ST11 predominates, blaKPC-2 is frequently carried on a distinct ΔTn6296 / IS26–ISKpn27–blaKPC-2–ΔISKpn6 non-Tn4401 mobile element (NTEKPC) housed on conjugative IncFII_pHN7A8 or IncFII/IncR chimeric plasmids. In high-resolution ICU genomic surveillance, these IncFII and IncX3 plasmids transfer across species boundaries from K. pneumoniae into Escherichia coli, Enterobacter hormaechei, Citrobacter freundii, and Serratia marcescens within the gastrointestinal tract of hospitalized patients—producing plasmid-mediated multispecies outbreaks that chromosomal housekeeping markers (16S ribosomal RNA or standard 7-locus MLST) fail to link without whole-genome plasmid and tRNA-island profiling.

Outer-Membrane Porin Constriction (OmpK35 and OmpK36)

High-level clinical carbapenem resistance (MIC ≥ 64 mg/L) rarely results from blaKPC expression alone; instead, it reflects kinetic synergy between periplasmic KPC hydrolysis and reduced outer-membrane drug influx through the major non-specific β-barrel porins OmpK35 (the K. pneumoniae orthologue of E. coli OmpF) and OmpK36 (OmpC). Epidemic ST258 and ST11 lineages commonly carry frameshift truncations that abolish the wider OmpK35 channel, leaving OmpK36 as the sole entry portal for zwitterionic carbapenems.

Under carbapenem selective pressure, ST258/ST11 isolates acquire a characteristic two-amino-acid insertion—either Gly134–Asp135 (GD duplication) or Thr134–Asp135 (TD duplication)—within the inward-folded Loop L3 constriction zone of the OmpK36 β-barrel pore. Crystal structures of OmpK36_GD show that this dipeptide insertion narrows the pore eyelet diameter by ~26%, severely restricting the diffusive flux of meropenem and ertapenem across the outer membrane so that periplasmic KPC-2 molecules hydrolyze incoming antibiotic molecules faster than they can reach Penicillin-Binding Proteins (PBP2 and PBP3).

Diazabicyclooctanes (Avibactam, Relebactam) and Cyclic Boronates (Vaborbactam)

Because classical mechanism-based β-lactam sulfone inhibitors (clavulanic acid, sulbactam, and tazobactam) are themselves hydrolyzed by the active deacylation machinery of KPC, two non-β-lactam structural classes were engineered in drug discovery to restore β-lactam efficacy against KPC-producing Enterobacterales:

1. Diazabicyclooctanes (DBOs: Avibactam and Relebactam): Combined clinically as ceftazidime–avibactam and imipenem–cilastatin–relebactam. The strained bicyclic urea core of avibactam reacts reversibly with Ser70 of KPC-2 (k_2/K_i ≈ 1.3 × 10⁴ M⁻¹ s⁻¹) to form a stable carbamoyl-enzyme linkage. Unlike clavulanate, avibactam does not undergo irreversible fragmentation; instead, it slowly decarbamoylates via ring recyclization to regenerate intact avibactam, resisting Glu166-mediated hydrolytic destruction.
2. Cyclic Boronic Acids (Vaborbactam): Combined clinically as meropenem–vaborbactam. The electrophilic boron atom of vaborbactam forms a reversible dative covalent bond with the γ-oxygen of Ser70, directly mimicking the sp³ tetrahedral oxyanion transition state (K_i ≈ 69 nM) and maintaining potent activity even in KPC-2/KPC-3 strains with OmpK35 truncation.

Ω-Loop Mutations (Asp179Tyr) and Collateral Sensitivity

Within years of the clinical introduction of ceftazidime–avibactam, treatment-emergent resistance appeared in patients infected with KPC-2 and KPC-3 K. pneumoniae. Whole-genome sequencing identified single-amino-acid substitutions or small insertions/deletions inside the Ω-loop (Arg164–Asp179), most frequently Asp179Tyr (D179Y), which converts KPC-3 into KPC-31 and KPC-2 into KPC-33.

In wild-type KPC, Asp179 forms a critical stabilizing salt bridge with Arg164 at the base of the Ω-loop, holding Glu166 and Asn170 in rigid alignment for deacylation. Replacing Asp179 with tyrosine (D179Y) breaks the Arg164–Asp179 salt bridge and disorders the Ω-loop. This structural loosening expands the active-site pocket so it binds the bulky oxyimino-aminothiazolyl side chain of ceftazidime with 10-fold to 20-fold higher affinity ("trapping" ceftazidime and reducing avibactam acylation efficacy), elevating the ceftazidime–avibactam MIC from 1 mg/L to ≥64 mg/L. However, because Glu166 is now displaced from its catalytic position on the disordered Ω-loop, KPC-31 and KPC-33 lose the ability to deacylate carbapenems—dropping meropenem and imipenem MICs back into the clinically susceptible range (≤1 mg/L). This evolutionary trade-off—termed collateral sensitivity or the "seesaw effect"—demonstrates how biophysical epistasis inside the Ω-loop constrains simultaneous resistance to ceftazidime–avibactam and meropenem–vaborbactam.

How does KPC differ biochemically from NDM-1?

KPC is an Ambler Class A serine β-lactamase that uses a catalytic serine residue (Ser70) to form a covalent acyl-enzyme ester intermediate and is inhibited by avibactam, vaborbactam, and relebactam, but unaffected by EDTA. NDM-1 is an Ambler Class B1 metallo-β-lactamase that uses two Zn²⁺ ions to activate a water/hydroxide nucleophile without forming a covalent intermediate; consequently, NDM-1 is inhibited by metal chelators like EDTA, resists avibactam and vaborbactam, and cannot hydrolyze aztreonam (whereas KPC hydrolyzes aztreonam efficiently).

What is the "seesaw effect" in KPC-31 and KPC-33 mutants?

When a KPC-producing Klebsiella pneumoniae strain under ceftazidime–avibactam treatment acquires the Asp179Tyr (D179Y) mutation in its Ω-loop (KPC-31 or KPC-33), breaking the Arg164–Asp179 salt bridge makes the Ω-loop flexible. This flexibility allows the enzyme to bind and protect against ceftazidime–avibactam (causing resistance), but simultaneously misaligns the Glu166 general base required to hydrolyze carbapenems—restoring clinical susceptibility to meropenem and meropenem–vaborbactam.

How do OmpK36 porin mutations amplify carbapenem resistance in KPC-producing Klebsiella?

Carbapenems must diffuse across the Gram-negative outer membrane through water-filled β-barrel porins (OmpK35 and OmpK36) to reach their targets in the periplasm. When OmpK35 is lost and OmpK36 acquires a Gly134–Asp135 (GD) or Thr134–Asp135 (TD) insertion inside its Loop L3 channel eyelet, the narrowed pore slows carbapenem entry by more than 70%, allowing periplasmic KPC enzymes to hydrolyze every incoming carbapenem molecule before cell-wall synthesis is inhibited.

1. Yigit, H., Queenan, A. M., Anderson, G. J., Domenech-Sanchez, A., Biddle, J. W., Steward, C. D., Alberti, S., Bush, K., & Tenover, F. C. (2001). "Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae." Antimicrobial Agents and Chemotherapy, 45(4), 1151–1161. https://doi.org/10.1128/AAC.45.4.1151-1161.2001
2. Ke, W., Bethel, C. R., Thomson, J. M., Bonomo, R. A., & van den Akker, F. (2007). "Crystal structure of KPC-2: insights into carbapenemase activity in class A β-lactamases." Biochemistry, 46(19), 5732–5740. https://doi.org/10.1021/bi700300u
3. Shields, R. K., Chen, L., Cheng, S., Chavda, K. D., Press, E. G., Snyder, A., Pandey, R., Doi, Y., Kreiswirth, B. N., Nguyen, M. H., & Clancy, C. J. (2017). "Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections." Antimicrobial Agents and Chemotherapy, 61(3), e02097-16. https://doi.org/10.1128/AAC.02097-16
4. Wong, J. L. C., Romano, M., Kerry, L. E., Kwong, H. S., Low, W. W., Brett, S. J., Clements, A., Beis, K., & Frankel, G. (2019). "OmpK36-mediated carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo." Nature Communications, 10(1), 3957. https://doi.org/10.1038/s41467-019-11756-y